T hrombolytic therapy with intravenous tissue plasminogen activator (tPA) is beneficial for patients with acute ischemic stroke within 4.5 hours of stroke onset. [1] [2] [3] Pooled analysis of randomized trials show that the benefit of tPA is strongly time dependent. 3, 4 Worldwide, stroke physicians have implemented continuous quality improvement programs to accelerate delivery of tPA, steadily reducing door-to-needle (DTN) times. [5] [6] [7] To guide further improvement of tPA delivery, it would be helpful to clarify 2 aspects of the time dependence of tPA benefit: (1) the additional benefit associated with hyperacute treatment in the first 60 minutes after last known well time, and (2) the shape of the time-benefit curve of tPA through 4.5 hours.
Until recently, tPA start in the first 60 minutes postonset, the golden hour, was not achievable except in a tiny proportion of patients. As a result, analyses of the relation of onset-to-treatment (OTT) time and outcome based on randomized trials have only considered times from 60 minutes onward, with the golden hour treated as terra incognita. 3, [8] [9] [10] However, recent developments make hyperacute tPA treatment within 60 minutes of onset attainable in clinical practice. Continued improvements in systems to shorten DTN times, to as low as an average of 20 minutes, 5 make it feasible to start tPA in emergency departments within 60 minutes postonset in very early arriving patients. Also, even faster tPA initiation can be performed with the use of mobile stroke unit ambulances equipped with computed tomography scanners, permitting prehospital initiation of thrombolysis. [11] [12] [13] [14] Both of these approaches, however, require substantial expenditures of labor and capital, which makes their cost-benefit uncertain. Information is needed on whether the degree of additional benefit gained with hyperacute treatment within the first hour is sufficient to justify these special efforts. 14 In addition, the shape of the time-benefit curve for tPA between 1 and 4.5 hours has not been previously directly studied. Prior time analyses imposed a linear relationship, rather than making the shape the subject of empirical investigation. 3, 8, 10, 15 But clinical trial data are also compatible with an exponential pace of benefit decline. 4 Larger registry data sets can provide insights into how quickly benefits of tPA decay with time and show whether the benefit of tPA declines with time in an exponential, linear, or other pattern.
METHODS
The Get With The Guidelines-Stroke Program (GWTG-Stroke) is a national registry launched by the American Heart Association and American Stroke Association to support continuous quality improvement of hospital systems of care for patients with stroke and transient ischemic attack. 16, 17 Details of the design and conduct of the GWTG-Stroke Program have previously been described. 17 In brief, the GWTG uses a Web-based patient management tool (Quintiles) to collect clinical data on consecutively admitted patients, to provide decision support, and to enable real-time online reporting features. 17 The GWTG-Stroke Program was made available in April 2003 to any hospital in the United States. 17 Each participating hospital received either human research approval to enroll patients without individual patient consent under the common rule or a waiver of authorization and exemption from subsequent review by their institutional review board. The institutional review board of the data analysis center at Duke University approved the study.
Data from hospitals that participated in the program any time between January 1, 2009, and September 30, 2013, were included in this analysis. The study focused on patients with acute ischemic stroke treated with tPA within 270 minutes (4.5 hours) of the last known well time. Detailed study inclusion and exclusion criteria are shown in online-only Data Supplement Figure I .
Analyzed outcomes included (1) in-hospital mortality, (2) discharge status (ordinal: home, acute rehabilitation, skilled nursing facility, or dead; and binary: home versus other), and (3) ambulatory status at discharge (ordinal: ambulatory without another person's assistance, ambulatory only with another person's assistance, nonambulatory, or dead; and binary:
Clinical Perspective
What Is New?
• In this large registry of >65 000 patients with ischemic stroke treated with intravenous tissue plasminogen activator, 878 patients were treated within the first 60 minutes after onset, a 10-fold increase over previously available data.
• Thrombolytic treatment within the first 60 minutes was associated with the highest rates of favorable discharge outcomes.
• Also, the shape of the time-benefit curve throughout the first 4.5 hours postonset was nonlinear for some outcomes.
• Discharge to home and discharge free of disability decayed more rapidly in the first 100 to 170 minutes after onset than later, whereas independent ambulation at discharge and in-hospital mortality declined in a steady fashion throughout the 4.5-hour window.
What Are the Clinical Implications?
• The superior outcomes with thrombolysis in the first 60 minutes and more rapid decay of benefit for some outcomes earlier after onset support intensive efforts to speed patient presentation and tissue plasminogen activator treatment start in all patients.
• The findings reinforce the importance of quality improvement programs to accelerate door-to-needle time, support further implementation of telemedicine systems enabling delivery of thrombolysis in rural and other frontline hospitals, and provide impetus for further research on the use of mobile stroke unit ambulances equipped with computed tomography scanners that enable faster, prehospital delivery of thrombolysis.
ambulatory without assistance versus other). Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 36 hours and severe systemic hemorrhage. In addition, for exploratory analysis, the modified Rankin Scale (mRS) at discharge was analyzed, during the time period after it began being collected in October 2012. The mRS was analyzed both over the full, 7-level (0-6) ordinal scale and dichotomized at 2 cut points. The binary analyses were: mRS 0 to 1 (excellent outcome; nondisabled), and mRS 0 to 2 (good outcome; functionally independent). Multivariable regression analysis was also performed to explore the relationship between OTT and clinical outcome of interests. For dichotomous outcomes, logistic regression with generalized estimating equations method with an exchangeable correlation structure was used to account for hospital clustering. These multivariable analyses adjusted for 23 patient-level and 7 hospital-level variables. Missing data for select key variables were imputed to the mode or median, but patients with missing National Institutes of Health Stroke Scale score (<7% of the total) were excluded from all regression analyses. For ordinal outcomes, adjusted rates were derived as an average of individual predicted probabilities computed for each response category and each OTT time epoch among all possible combinations of covariates using a multivariate generalized logit model for nonordered categorical outcomes. All P values were 2-sided and statistical significance was defined as P<0.05.
Statistical Analysis
The shape of the relationship between OTT and binary outcomes was assessed using binary logistic regression and OTT restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles to avoid any presumption of linearity. 18, 19 To generate time-benefit curves, outcome-specific predicted probabilities for each value of OTT within the observed range (18-270 minutes) were computed while setting all other variables in the model to mean values. To visually assess linearity, odds ratios for each OTT value were computed with the outcome rate at the golden hour (60 minutes) as the reference. Wald χ 2 tests for nonlinearity were also performed. SAS (version 9.3; SAS Institute) statistical software was used for all statistical analyses.
RESULTS
Among all stroke patients in the GWTG-Stroke registry during the study period, 1 065 875 were patients with ischemic stroke admitted to hospitals with ≥30 cases and <25% of missing data in medical history panels (online-only Data Supplement Figure I ). Among these, 65 384 patients with ischemic stroke from 1456 sites were treated with tPA within 4.5 hours of symptom onset and constitute the study population. The OTT time for tPA administration was median, 141 minutes; interquartile range, 110 to 173 (mean, 145±46). There were 878 (1.3%) patients with OTT time of 0 to 60 minutes, 6490 (9.9%) patients with OTT time of 61 to 90 minutes, 46 457 (71.1%) patients with OTT time of 91 to 180 minutes, and 11 559 (17.7%) patients with OTT time of 181 to 270 minutes.
The general characteristics of patients treated with tPA in each of the 4 time epochs are shown in Table 1 , and unadjusted and adjusted odds ratios of potential factors associated with hyperacute therapy within 60 minutes of onset are shown in Table 2 . Patient-level factors independently associated with receiving tPA within the first 60 minutes after adjustment included: more severe presenting neurological deficit (higher National Institutes of Health Stroke Scale score); arrival during regular, weekday hours; and less frequent arrival by Emergency Medical Services ambulance. The relationship between age and hyperacute thrombolysis differed in younger versus older patients: up to age 65 years, increasing age was associated with higher likelihood of thrombolysis in the golden hour; but after age 65 years, increasing age was associated with lower likelihood of hyperacute thrombolysis. Hospital-level factors independently associated with receiving tPA within the first 60 minutes included: higher annual volume of tPA-treated cases; not being a Primary Stroke Center; and being in the West. In addition, patients treated in the golden hour had shorter intervals from last known well to emergency department arrival and DTN times than longer OTT groups.
Unadjusted rates of efficacy and safety outcomes in the 4 OTT groups are shown in online-only Data Supplement Table I . Overall, at discharge, 42.5% of patients were sent home and 42.0% were ambulating independently. In the cohort enrolled after the program initiated collection of discharge mRS information, 28.5% were nondisabled (mRS 0-1), and 38.0% were functionally independent (mRS 0-2). sICH occurred in 4.4%, severe systemic hemorrhage in 1.0%, and in-hospital death in 7.5%.
The association of OTT time epoch with adjusted outcomes is shown in Table 3 . In the adjusted analysis, for patients treated in the first 60 minutes, in comparison with those treated after >60 minutes of onset, all dichotomized efficacy outcomes were better, including increased odds of discharge to home, independence in ambulation, freedom from disability (mRS 0-1), and functional independence (mRS 0-2). The largest effect was seen for excellent outcome (mRS 0-1), with odds ratio 1.72 (95% CI, 1.21-2.46). In contrast, although sICH, systemic hemorrhage, and mortality increased across all 4 analyzed OTT time epochs, these safety out- comes were not distinctively further reduced among hyperacutely treated patients. Considering ordinal efficacy outcomes, each earlier OTT time epoch was associated with an incremental beneficial shift, including for ambulatory status at discharge, discharge destination, and disability level at discharge (Figure 1 ). The continuous time-benefit curves for 4 dichotomized efficacy and safety outcomes are shown in Figure 2 (adjusted probability analysis), online-only Data Supplement Figure II (unadjusted probability analysis), and onlineonly Data Supplement Figure III (odds ratio analysis) . A nonlinear relation between rates of discharge to home and OTT was noted (adjusted P for nonlinearity=0.006); the probability of discharge to home declined steadily from OTT of 20 minutes to 170 minutes (10.5 fewer patients per thousand treated discharged home with every 15-minute delay) with a less steep decline between 171 and 270 minutes (2.6 fewer patients discharged home per thousand treated with every 15-minute delay). There was a visually nonlinear relation between discharge free of disability (mRS 0-1) and OTT, with steeper decline from 20 to 100 minutes and slower thereafter, although formal testing for nonlinearity did not reach statistical significance (adjusted P for nonlinearity=0.34). For independent ambulation at discharge, a linear relationship with OTT was observed throughout the 4.5-hour window, with 9.6 fewer per 1000 treated per 15-minute delay. Similarly, for in-hospital mortality, a linear relation with OTT was noted, with 1.4 more per 1000 treated per 15-minute delay.
DISCUSSION
In this study of >65 000 patients treated with intravenous tPA throughout the United States, treatment in the golden hour, within 60 minutes of onset, was associated with higher rates of excellent early outcome in comparison with later treatment. After adjustment for other outcome predictors, at the time of discharge, nearly one-half of patients treated in the golden hour were ambulating independently, nearly half could be sent directly home, and more than one-third were free of disability (mRS 0-1). In addition, over the entire 4.5-hour window for treatment, the pace of the decline in benefit of tPA with longer OTT times was found to be nonlinear for discharge to home, with more rapid benefit loss in the first 170 minutes than later, potentially mildly nonlinear for discharge free of disability with the steepest loss of benefit over the first 100 minutes, and linear throughout for independent ambulation and in-hospital mortality.
Our findings substantially enlarge the reported experience with hyperacute thrombolysis within 60 minutes of onset. The only randomized trials of tPA to specifically report treatment within 60 minutes of onset were the 2 National Institute of Neurological Disorders and Stroke tPA Study trials; only 2 patients received study infusion in the first 60 minutes and both received pla- cebo. 20, 21 The golden hour cohort size of 878 patients in the current study exceeds by an order of magnitude the largest prior report from the PHANTOM-S study (Prehospital Acute Neurological Treatment and Optimization of Medical care in Stroke). 12 In our study, in comparison with treatment beyond the first 60 minutes, hyperacute thrombolysis in the first 60 minutes was associated after adjustment with having 25% greater odds of discharge to home, 22% greater odds of independent ambulation at discharge, 72% greater odds of being nondisabled (mRS 0-1) at discharge, and 58% greater odds of being functionally independent (mRS 0-2) at discharge. The PHANTOM-S study showed similar results for the 1 functional outcome it examined, that patients who received tPA treatment in the golden hour were more likely to be discharged home than patients with a longer OTT time. 14 The results of our study provide reliable information on the magnitude of improved early outcome associated with tPA treatment within the first 60 minutes after stroke onset.
Our findings additionally provide novel information regarding the shape of the time-benefit curve for tPA throughout the 0-to 4.5-hour time window for outcomes at discharge. Prior studies have generally simply assumed a linear decline of benefit and have had insufficient sample sizes to explore time-benefit variation at a more granular level. 3, 4, 8, 10 With the larger GWTG-Stroke cohort, we were able to delineate the time-benefit curve in a data-driven manner, making no assumptions regarding linear, exponential, or other. We found that, for excellent functional outcome (discharge to home), there was a mildly nonlinear relationship with OTT, with 2.5-fold faster loss of benefit in the first 170 minutes than the next 100 minutes. Analysis of another index of excellent outcome, mRS 0 to 1, was constrained by lower sample size (because of the more recent addition of this field to the registry), but also suggested a nonlinear time-benefit curve, with faster decline in the first 60 to 100 minutes than later, although this was not statistically significant. In contrast, for good functional outcome (ambulating independently at discharge) and for mortality, benefit declined linearly throughout the 4.5-hour treatment window. That superior outcome is disproportionately affected by OTT in the early part of the treatment window is consonant with dependence of excellent functional outcome on the achievement of the smallest final infarct volumes. 22, 23 Despite the superior outcomes associated with treatment in the first 60 minutes of onset, only 1.3% of tPA patients in the GWTG-Stroke cohort were treated in this early time frame. Hyperacute treatment within 60 minutes of onset required rapid responses by both prehospital and in-hospital systems of care. In comparison with other patients, patients treated in the golden hour arrived much earlier at the emergency department (median, 22 minutes) and had much shorter DTN times (median, 30 minutes). Even faster average DTN times have been attained at best-practice hospitals worldwide, often using direct paramedic delivery of patients to the computed tomography suite rather than the emergency department. 5, 24 The superior outcomes with thrombolysis in the golden hour in the current study further emphasize the importance of system interventions to accelerate prehospital and emergency department stroke care processes. Multiple interventions have been found beneficial in shortening onset to tPA times, including prearrival notification by Emergency Medical Services providers, written protocols for acute triage and patient flow, single call system to activate all stroke team members, and direct delivery of the patient -the computed tomography suite . Variables for adjustment: age, sex, race, atrial fibrillation, prosthetic valve, CAD-prior MI, carotid stenosis, diabetes mellitus, peripheral vascular disease, hypertension, smoking, dyslipidemia, prior stroke/TIA, NIHSS as continuous, arrival and admission information (EMS/on-off hours), hospital size, hospital region, rural location, academic hospital, primary stroke center, annual volume of ischemic stroke admission, annual volume of tPA administration, interaction term age × NIHSS, and medications before admission (antiplatelets, anticoagulants, antihypertension, cholesterol reducers, and medications for diabetes mellitus). CAD indicates coronary artery disease; CI, confidence interval; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; OTT, onset-to-treatment; TIA, transient ischemic attack; and tPA, tissue plasminogen activator.
*P values are computed using Wald tests. Global P values for the overall association of OTT groups with the outcomes are given, and P values for the comparison of each category with the reference group 181-270 min or OTT golden hour versus longer times.
†mRS 0-1 and 0-2 at discharge: limited to October 2012 through September 2013 when mRS started to be collected. Our results identify several particular targets for system improvement to onset-to-door and DTN times. Patients who arrived at the emergency department beyond working hours were less likely to be treated within the golden hour, indicating a need for improved staffing solutions for off-hour time periods. Arrival by Emergency Medical Services ambulance actually occurred less often in patients treated within 60 minutes of onset than in patients treated 61 to 180 minutes after onset. The alarm-to-door time (interval from 911 call to emergency department arrival) for Emergency Medical Servicestransported stroke patients in the United States is typically about 45 minutes, reflecting travel of the ambulance to the scene, paramedic activities on scene, and travel from scene to door. 27 This overall alarm to door time affords little opportunity for treatment within 60 minutes of onset. These findings support efforts to shorten prehospital care intervals to meet national targets. 28 Hospitals with higher annual volumes of tPA treatment were more often able to provide thrombolysis within 60 minutes of onset, suggesting potential benefits to avoiding duplicate services when not mandated by geographic distribution.
This study also provides important reassurance regarding the safety of rapid thrombolysis initiation within 60 minutes of onset. It is theoretically possible that the very fast diagnostic and treatment algorithms required to achieve treatment within 60 minutes of onset would be associated with imperfect patient selection and therapeutic management, off-setting gains from earlier reperfusion when there is a greater volume of still-salvageable threatened tissue. 29 However, we found that hyperacute treatment within 60 minutes of onset was as safe as later therapy in avoiding sICH or severe systemic bleeding. These findings accord with previous GWTG-Stroke studies showing that shorter OTT and DTN times are associated with reduced of tPA complications including sICH. 6, 15 Accordingly, the available evidence suggests that thrombolysis within the golden hour reduces complications, in addition to improving functional outcome.
This study has several limitations. First, it has the inherent limitation of a registry-based study. However, to optimize data quality, the GWTG-Stroke Program includes detailed training of site chart abstractors, standardized case definitions and coding instructions, predefined logic and range checks on data fields at data entry, audit trails, and regular data quality reports for all sites. 17 Second, longer-term, postdischarge functional outcome, eg, at 90 days, was not investigated, because postdischarge data were not collected in the GWTG-Stroke registry during the study period. Assessment at discharge requires some degree of rater surmise regarding the patient's degree of independence (mRS 2 versus 3), because the patient has not yet fully attempted community integration. Also, this early assessment does not reflect further improvements in function that may occur over subsequent months. However, studies have shown that functional outcomes at discharge highly correlate with outcomes at 3 months. 30, 31 Third, our results analyze the effects of earlier time to lysis versus later time to lysis, not of earlier time to lysis versus earlier time to placebo. Fourth, patients treated in the first 60 minutes represented only 1.3% of the data set. Although this constrained study power, this population of 878 patients is an order of magnitude larger than in prior reports. Adjusted rates for ordinal outcomes for onset-to-treatment time windows for functional status at discharge (A), discharge destination (B), and modified Rankin Scale at discharge (C) (covariates for adjustment same as models in Table 3 ). OTT indicates onset-to-treatment; Rehab, rehabilitation; and SNF, skilled nursing facility.
CONCLUSIONS
In broad national US clinical practice, in comparison with later time epochs, hyperacute treatment with tPA in the golden hour is associated with increased independent ambulation at discharge, discharge to home, and freedom from of disability or dependence at discharge. Over the entire 4.5-hour guideline-endorsed tPA time window, rates of being disability-free at discharge and discharge to home decay more rapidly in the first 100 to 170 minutes of stroke OTT time, whereas independent ambulation at discharge and in-hospital mortality decline in a linear fashion throughout. These findings lend further support of intensive efforts to speed patient presentation and the start of tPA treatment in all patients, including increasing the frequency of treatment within stroke's golden hour. The adjusted predicted probabilities scales of the association between OTT and 4 discharge outcomes: discharge to home (A), free of disability (mRS 0-1) at discharge (B), independent ambulation at discharge (C), and in-hospital mortality (note different y-axis scale) (D). CI indicates confidence interval; mRS, modified Rankin Scale; OTT, onset-to-treatment; and PROB, probability.
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